Entera Bio Q3 Loss Widens to $15.6M on Warrant Charge

Entera Bio Ltd. (NASDAQ: ENTX) reported a net loss of $15.6 million, or $0.11 per ordinary share, for the quarter ended September 30, 2026, against a $3.2 million loss, or $0.07 per share, a year earlier. The Israeli oral-peptide developer ended the period with $265.9 million in cash and cash equivalents plus $6.5 million in restricted cash, following a July 2026 private placement that raised roughly $275.0 million in gross proceeds. Entera said it expects first clinical site activation for its EB613 osteoporosis Phase 3 study in late 2026.

Context — Why Entera's Q3 Loss Matters Now

Entera's quarterly loss more than quadrupled year over year, but the driver was accounting rather than operations. The company attributed the swing primarily to a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in its April 2026 and July 2026 private placements, which were reclassified to equity in August 2026. That item sits below the operating line and does not consume cash.

Operating expenses tell a different story. Research and development rose to $4.9 million from $1.6 million, a $3.3 million increase the company tied to start-up activities for the EB613 Phase 3 program and work under its OPKO collaboration. General and administrative costs climbed to $2.3 million from $1.6 million.

Total operating expenses of $7.3 million compare with $3.3 million in the prior-year quarter. The gap between the $7.3 million operating loss and the $15.6 million net loss is almost entirely the warrant charge plus $8.3 million of net financial expenses, versus $56,000 of net financial income a year earlier.

What changed to trigger the spending step-up is the regulatory green light Entera described in June 2026. The company said the FDA accepted its proposed registrational development plan for EB613, clearing the path to a randomized, double-blind, placebo-controlled Phase 3 trial with a primary endpoint of percent change from baseline in total hip BMD at Month 12.

For a clinical-stage company with no revenue, the balance sheet is the story. Entera's cash position moved from $7.1 million at December 31, 2025 to $265.9 million at September 30, 2026, a transformation funded by outside investors rather than operations. The company said its cash resources should fully fund the EB613 Phase 3 registrational program through topline results and an anticipated NDA submission, and support operations into 2030.

Data — What Entera's Q3 2026 Numbers Show

The headline figures are straightforward. Cash and cash equivalents stood at $265.9 million on September 30, 2026, versus $7.1 million at year-end 2025. Restricted cash was $6.5 million, primarily designated to fund the OPKO collaboration, down slightly from $7.8 million. Total assets reached $277.0 million against $16.0 million at December 31, 2025. Total liabilities were $2.8 million, leaving shareholders' equity of $274.3 million.

The income statement shows the cost of that build-out. Revenues and cost of revenues were both zero in each period. R&D of $4.9 million and G&A of $2.3 million produced total operating expenses of $7.3 million, compared with $3.3 million a year earlier. Net financial expenses of $8.3 million replaced $56,000 of net financial income.

Weighted average shares outstanding used for basic and diluted loss per share jumped to 145.1 million from 47.1 million, which is why the per-share loss rose only to $0.11 from $0.07 despite the far larger net loss. The July 2026 placement was oversubscribed, led by existing investor BVF Partners L.P. with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital and Catalio Capital Management, among others.

The company did not disclose placement agent fees or offering expenses, so the net proceeds figure is not available from the report.

Analysis — What Entera's Cash Pile Means for ENTX

The funding removes the near-term financing risk that dominates small-cap biotech equity stories. Entera now carries $274.3 million of shareholders' equity against a $2.8 million liability stack, and it says the money covers the EB613 registrational program through topline data and an NDA filing. That shifts the analytical question from solvency to execution.

Execution means enrollment. Entera said the Phase 3 study is expected to enroll approximately 900 postmenopausal women with osteoporosis, randomized 2:1 to EB613 (roughly 600) or placebo (roughly 300). Eligible participants are women aged 50 to 90 and at least five years past their last menstrual period, with osteoporosis diagnosed by DXA and a BMD T-score of -2.5 or lower at the lumbar spine, total hip or femoral neck. Those completing 12 months will be eligible for an extension study through Month 24.

The counter-argument is timeline. Entera targets first site activation in late 2026 and topline results in the second half of 2028. That is a long runway for a single asset, and the company itself lists clinical trial results, FDA interpretation of its data, and reliance on third parties to conduct trials among the risks that could change outcomes.

On the regulatory side, Entera plans to use the 505(b)(2) pathway, with the NDA package including a scientific bridging analysis to Forteo (teriparatide SC injection, Eli Lilly) plus separate population PK and PK substudies, and a transiliac crest bone biopsy substudy in a small patient subset. That bridging strategy is what allows an oral PTH(1-34) tablet to reference an approved injectable rather than run a full standalone program.

Positioning follows the cap table. The July placement drew a long list of specialist healthcare funds, and the $7.5 million warrant remeasurement reflects how those instruments moved from liability to equity treatment. Sector read-across is limited: Entera is a single-asset story, so its spending is a signal about oral peptide manufacturing and clinical site capacity rather than a broad biotech demand indicator.

Outlook — What to Watch for Entera Bio

The near-term catalyst is first site activation for the EB613 Phase 3 study, which Entera expects in late 2026. Enrollment pace after that is the metric that determines whether the second-half 2028 topline target holds. The company also said it is conducting IND-enabling studies for EB612, its oral acylated PTH(1-34) replacement tablet for hypoparathyroidism developed with OPKO Health, and plans to initiate a Phase 1 single ascending dose study in 2027.

Board composition changes on December 1, 2026, when Laura Hamill and Juan Camilo Arjona Ferreira join as directors. Hamill most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, and Arjona Ferreira is Head of Research & Development and Chief Medical Officer at Organon & Co.

On the data side, Entera presented Phase 2 post-hoc analysis at ASBMR 2026 showing enhanced changes in bone turnover markers in women with T-scores of -2.5 or lower, the population it intends to enroll in Phase 3. The report gives no price levels, moving averages or index comparables for ENTX, so no technical thresholds can be stated. The watch items are enrollment disclosure, any further FDA correspondence, and the EB612 IND timeline.

Frequently Asked Questions

Why did Entera Bio's net loss jump to $15.6 million in Q3 2026?

The increase was driven mainly by a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in Entera's April 2026 and July 2026 private placements, which were reclassified to equity in August 2026. Higher R&D spending on EB613 Phase 3 start-up activities and the OPKO collaboration, plus $8.3 million of net financial expenses, accounted for the rest.